AFMD 250117 2.50P (AFMD250117P2500) Stock Options, News & Quotes

1.30
0.000.00%

15min DelayTrading Dec 23 09:48 ET

1.30High1.30Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 9 12:35

NEWS

$Affimed NV (AFMD.US)$
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...

This_Guy

Dec 8 17:23

$Affimed NV (AFMD.US)$
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.

Trytosaveabit

Dec 8 15:39

Watching 12/9/24 PR / New data released 12//8

$Affimed NV (AFMD.US)$ Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...

Jaguar8

Dec 8 11:00

NEWS SUNDAY 12/8

$Affimed NV (AFMD.US)$
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...

Jaguar8

Dec 8 02:14

🟢Watchlist December 9 Monday. Trading a stock is YOUR DECISION and you should be SOLELY ACCOUNTABLE for it. NFA.

$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...